The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting
Open accessAbstract
BACKGROUND: Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy. METHODS: We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment in patients who had a poor response to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment. The primary end point was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 year after stent implantation. For patients in the monitoring group, the VerifyNow P2Y12 and aspirin point-of-care assays were used in the catheterization laboratory before stent implantation and in the outpatient clinic 2 to 4 weeks later. RESULTS: In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an additional bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure. The primary end point occurred in 34.6% of the patients in the monitoring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval [CI], 0.98 to 1.29; P=0.10). The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional-treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P=0.77). The rate of major bleeding events did not differ significantly between groups. CONCLUSIONS: This study showed no significant improvements in clinical outcomes with platelet-function monitoring and treatment adjustment for coronary stenting, as compared with standard antiplatelet therapy without monitoring. (Funded by Allies in Cardiovascular Trials Initiatives and Organized Networks and others; ARCTIC ClinicalTrials.gov number, NCT00827411.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, large, superiority RCTs have failed to show a higher efficacy of routine platelet-function testing in guiding antiplatelet therapy post-PCI.322,322a”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [322]
In the citing paper
“Current evidence does not support platelet function testing to adjust DAPT.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [322]
In the citing paper
“Despite initial enthusiasm, multiple large, randomized studies have failed to show any clinical benefit when antithrombotic regimens are adjusted on the basis of platelet function testing.60–62”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationGuidelines on myocardial revascularization
Wijns, W. C., Kolh, P. H., Danchin, N., Mario, C. D., Falk, V., Folliguet, T. A., Garg, S., Huber, K., James, S. K., Knuuti, J., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq277 · Cited by 3,228
Price, M. J. (2011) · JAMA · doi:10.1001/jama.2011.290 · Cited by 1,311
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D. J., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,158
Bonello, L., Tantry, U. S., Marcucci, R., Blindt, R., Angiolillo, D. J., Becker, R. C., Bhatt, D. L., Cattaneo, M., Collet, J., Cuisset, T., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.047 · Cited by 1,151
Self-citationPrasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J. T., Bal, E. T., Deneer, V. H. M., Harmsze, A. M., der Heyden, J. A. S. V., Rensing, B. J. W. M., et al. (2010) · JAMA · doi:10.1001/jama.2010.181 · Cited by 850
Mehta, S. R., Tanguay, J., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H., Budaj, A., Avezum, Á., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61088-4 · Cited by 812
Self-citationThrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–883 of 883
The role of clopidogrel in the management of ischemic heart disease
Homan, D. J., & Price, M. J. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283606957
[Specific care plan in different stages of Alzheimer's disease].
Hein, C., Villars, H., & Nourhashémi, F. (2011) · PubMed
Assessment Methods for Aspirin-mediated Platelet Antiaggregation in Type 2 Diabetic Patients
Gómez, J. M. C., Puerto, M. A. N., Martínez, J. A., Barragan, M. I. D. M., Santigosa, P. L. P., Burguillos, F. J. S., Casimiro, F. J. M., & Torres, L. P. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000084
Antiplatelet Therapy Monitoring
Miller, C. H., & Roshal, M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397164-7.00137-3
Coronary thrombosis in diabetes: Are we doing enough?
Ajjan, R. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116663795
Vivar, P. C. (2016) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Peri‐procedural Platelet Function Testing in Risk Stratification and Clinical Decision Making
Gurbel, P. A., Liu, F., Chen, G., & Tantry, U. S. (2016) · Interventional Cardiology · doi:10.1002/9781118983652.ch47
Gremmel, T. (2016) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Conundrums of Platelet Function Testing
Sarma, A. A., & O’Donoghue, M. L. (2017) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.004872
ANTARCTIC: platelet function testing to adjust therapy – Authors' reply
Montalescot, G., & Cayla, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30781-x
Self-citationFerreira, P. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2017.tde-16052017-114902
Use of platelet function testing to guide the timing of coronary artery bypass surgery
McMahon, S. R., & Schneider, D. J. (2017) · Coronary Artery Disease · doi:10.1097/mca.0000000000000507
Assessment of thrombogenicity in stroke
Yamazaki, M. (2017) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.28.297
ANTIPLATELET THERAPY IN THE PREVENTION OF CEREBROVASCULAR ACCIDENTS
Rodionova, O. V., Сорокоумов, В. А., Вавилова, Т. В., Bogatenkova, J. D., Мнускина, М. М., Крупоткина, И. Г., & Isaeva, L. A. (2017) · The Scientific Notes of the Pavlov University · doi:10.24884/1607-4181-2017-24-1-15-21
Nathan, S., & Conway, B. (2017) · Springer eBooks · doi:10.1007/978-3-319-56042-7_29
Gori, A. M., Giusti, B., & Marcucci, R. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.10.026
Martínez, G., Adasme, M., Fuensalida, A., Mandiola, J., Cortés, M., Potthoff, M., Méndez, M., & Martínez, A. (2017) · Revista chilena de cardiología · doi:10.4067/s0718-85602017000300200
y, P. A., Bayés‐Genís, A., de Isla, L. P., Sanchís, J. M., & Heras, M. (2016)
ARE THERE ANY REASONS FOR WIDE USE OF PLATELET FUNCTION TESTS IN CLINICAL LABORATORY PRACTICE?
Dobrovolsky, A. B., & Titaeva, E. V. (2018) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2018-1-140-142
Kleiman, N. S. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2018.02.034
DeGrado, J. R., & Anger, K. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-71240-6_9
Buziashvili, Y. I., Кокшенева, И. В., Какауридзе, М. А., Abukov, S. T., Инаури, И. А., & Turakhonov, T. K. (2018) · Russian Journal of Cardiology and Cardiovascular Surgery · doi:10.17116/kardio20181144
Freeman, P. M. (2018) · ORCA Online Research @Cardiff (Cardiff University)
Sin, P. S.-P., Yang, A., Pon, Q., Lavoie, A., Crawford, J. J., Harenberg, S., Zimmermann, R. H., Booker, J., Kelly, S., Lavi, S., et al. (2018) · Journal of Thrombosis and Circulation Open Access · doi:10.4172/2572-9462.1000128
Biomarkers for Antiplatelet Therapy
Dadu, R. T., & Kleiman, N. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00013-2
Lorenzo, A. D., Dutra, M., de Mattos, M. A., Rey, H., & Tibiriçá, E. V. (2019) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20188001
Bătăilă, V., Popa‐Fotea, N., Onciul, S., Câlmâc, L., Scafa‐Udriște, A., Cherry, A., Stănciulescu, D., & Dorobanţu, M. (2019) · Medicina Moderna - Modern Medicine · doi:10.31689/rmm.2019.26.3.111
Aradi, D., Komócsi, A., Kancz, S., Nagy, G. G., Kiss, R. G., & Merkely, B. P. (2019) · Cardiologia Hungarica · doi:10.26430/chungarica.2019.49.4.267
Platelet Function Testing and Clinical Outcomes
Schneider, D. J. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.09.007
CCI and CIT 2020—A special year of the special issue
Gao, R., & Xu, B. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28808
Résistance aux antiplaquettaires : mythe ou réalité ?
Bordet, J. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30099-x
Nova, T. T., Jahan, I., Momenuzzaman, N., Rabbi, S. N. I., Binder, T. M. C., Islam, M. S., Islam, M. R., Hasnat, A., & Nahar, Z. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.04.325258
Antiplatelet Therapy in Secondary Prevention in Patients with Ischaemic Peripheral Arterial Disease
Chrbolka, P., Palúch, Z., Chrbolka, P., & Pallag, G. (2020) · Journal of Integrative Cardiology Open Access · doi:10.31487/j.jicoa.2020.06.05
Abu‐Much, A., & Asher, E. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.01.013
Fibrinolytic, antiplatelet, and anticoagulant drugs in acute coronary syndromes
Halvorsen, S., Gargiulo, G., Valgimigli, M., & Huber, K. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198849346.003.0040
Monitoring and tailoring the P2Y12 ADP receptor blocker therapy
Bolek, T., Korpallová, B., Urban, L., Marko, J., Benko, J., & Prídavková, D. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.029
DOAC drug levels: Does “knowing” lead to safer care?
Hanigan, S., & Barnes, G. D. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.10.028
Atasoy, D., Dinç, H., Oğuz, Ş., & Sönmez, M. (2021) · The European Research Journal · doi:10.18621/eurj.848440
Guo, G. (2021) · Research Square · doi:10.21203/rs.3.rs-1201847/v1
Ticagrelor in Acute Coronary Syndromes
Howard, C. (2015) · doi:10.26686/wgtn.17014211
Balance of Ischemia and Bleeding in Selecting Intensity and Duration of Antithrombotic Regimens
Cao, D., Camaj, A., & Mehran, R. (2022) · Interventional Cardiology · doi:10.1002/9781119697367.ch43
Peri‐procedural Platelet Function Testing in Risk Stratification and Clinical Decision Making
Gurbel, P. A., Navarese, E. P., Myat, A., & Tantry, U. S. (2022) · Interventional Cardiology · doi:10.1002/9781119697367.ch45
(2013) · Circulation · doi:10.1161/01.cir.0000437012.93100.d5
Weber, C. F., Zacharowski, K. D., & Jámbor, C. (2015) · Springer eBooks · doi:10.1007/978-3-642-54675-4_27-1
(2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.06.018
Monsuez, J. J. (2013) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(13)70499-1
Antiplatelet treatment in acute myocardial infarction
Bergmeijer, T. O. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230530tb
P2Y12 Inhibitors in STEMI Patients — One Size Does Not Fit All
Patel, R. C., Jones, J. E., & Stouffer, G. A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07497-2
Greco, A., & Capodanno, D. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0015
Personalized antithrombotic therapy: measuring individual variation and monitoring
van den Broek, W. W. A., ten Berg, J. M., Sibbing, D., & Rizas, K. D. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0029
Antithrombotic Therapy for Heterogeneous Causes of Stroke
Kalanuria, A. A., Walker, M., & Ling, G. S. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-49963-0_15
John Steinbeck in cardiology: of guidelines and giants
Romagnoli, E., Aurigemma, C., Biondi‐Zoccai, G., & Burzotta, F. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06635-3
(2015) · ASA Monitor · doi:10.1097/01.asm.0001073512.81363.4f
Personalized Platelet Protocols: Progress, Pitfalls, and Potential
Kallmes, D. F., & Altschul, D. (2025) · Radiology · doi:10.1148/radiol.250488
Hamza, M., Karamat, M., Harmouch, K. M., Alamzaib, S. M., Jabeen, S., Basit, J., Bhanushali, K. B., Ved, R., Rashdi, A., Almani, M. U., et al. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07747-5
Efficacy of P2Y12 receptor blockers: current approaches and prospects
Anisimova, A. S., & Vasilieva, E. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6426
Laboratory Monitoring-Guided Antiplatelet Therapy
Galli, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_12
Anisimova, A. S., Rusakovich, G., Maryukhnich, E., Ivanova, O., Kalinskaya, A. I., Elizarova, A., Dukhin, O., Kordzaya, H., Bugrova, A. E., Brzhozovskiy, A. G., et al. (2025) · Kardiologiia · doi:10.18087/cardio.2025.10.n3000
Samprasit, N., Kulthanachairojana, N., Phanudulkitti, C., & Hemapanpairoa, J. (2025) · Value in Health Regional Issues · doi:10.1016/j.vhri.2025.101565
Guided or Unguided Antiplatelet Therapy: Clarifying the Ambiguity
Liang, H.-W., & Wang, T. (2025) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2025.16
Lei, M., Li, Y., Wang, J., Sun, X., Li, C., Wang, X., Zhao, Z., & Xue, Z. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm41544
Déterminants de l'athérothrombose chez le patient diabétique de type II
Ghannudi, S. E. (2013) · theses.fr (ABES) · doi:10.70675/bfcde275z318dz4944z883azc15c9350b7ac
Anti-plaquettaires et risque hémorragique : rôle du CD40L
Grosdidier, C. (2014) · theses.fr (ABES) · doi:10.70675/d2361bc1zbad2z4fafz8d2cze117614aca75
Rebello, J. V., Shah, A., Karattuthodi, M. S., Mai, C.-W., & Elnaem, M. H. (2026) · Acta Clinica Belgica · doi:10.1080/17843286.2026.2653688
Mahmoud, A. A., & Kouides, P. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-13858-3_46
Basit, J., Ahmed, M., Burhan, M., Ahsan, A., Zahra, R., Hamza, M., Usman, M., Ahmed, R., Kawsara, A., Daggubati, R. B., et al. (2026) · Coronary Artery Disease · doi:10.1097/mca.0000000000001649
Maltseva, A. S., Rusakovich, G., Maryukhnich, E., Ivanova, O., Kordzaya, H., Elizarova, A., Kononikhin, A. S., Bugrova, A. E., Zakharova, N. V., Николаев, Е. Н., et al. (2026) · Kreativnaya kardiologiya · doi:10.24022/1997-3187-2026-20-1-115-127
Bradaric, C., Kramer, C., Müller, A. M., Bernlochner, I., Haller, B., Kafka, A., Brugger, M., Bergmann, K., Cassese, S., Kastrati, A., et al. (2026) · VASA · doi:10.1024/0301-1526/a001300
Abdelgader, M., Khalid, R., Yadav, K., Ahmed, S. E. S., Veerasamy, M., Das, A., & Bulluck, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51947
State of the Art: Personalized Antiplatelet Therapy by Genotype and Platelet Function Testing
Gurbel, P. A., Jeong, Y., Navarese, E. P., Kubica, J., Ramotowski, B., & Tantry, U. S. (2026) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.70794
Serial Platelet Function-Guided Antiplatelet Modulation After STEMI: A Randomized Pilot Study
Jurin, H., Hadžibegović, I., Samardžić, J., Bulum, J., Škorić, B., Čikeš, M., Planinc, I., Ostojić, Z., Tagasovski, I., & Miličić, D. (2026) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484261483397
Izaguirre, S., Belits, A., Salottolo, K., Pirahanchi, Y., Kim, D. Y., Bar‐Or, D., & Burrell, C. (2026) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2026.112317
Echelman, D., & Frelinger, A. L. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.09.018
Camera, M., Brambilla, M., Becchetti, A., Conti, M., Bonomi, A., Trabattoni, D., Werba, P., Campodonico, & Marenzi, G. (2024) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10715707
Snyder, D., Madhavan, M. V., Shin, S., Chen, N., Prasad, M., Collins, M. B., McEntegart, M. B., Kirtane, A. J., & Moses, J. W. (2026) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2026.10.013
On platelet biology and cardiovascular disease
van Holten, T. C. (2013) · Utrecht University Repository (Utrecht University)
Metadata
- Authors
- Collet, J.-P., Cuisset, T., Rangé, G., Cayla, G., Elhadad, S., Pouillot, C., Henry, P., Motreff, P., Carrié, D., Boueri, Z., Belle, L., Van Belle, E., Rousseau, H., Aubry, P., Monségu, J., Sabouret, P., O'Connor, S. A., Abtan, J., Kerneis, M., Saint-Etienne, C., Barthélémy, O., Beygui, F., Silvain, J., Vicaut, E., & Montalescot, G.
- Affiliations
- Pitié-Salpêtrière Hospital (FR)
- Hôpital de la Timone (FR)
- Les Hôpitaux de Chartres (FR)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Hôpital Lariboisière (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Hôpital Rangueil (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- HIA du Val-de-Grâce à Paris (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-11-29
- Volume
- 367
- Issue
- 22
- Pages
- 2100-2109
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2145323902
- Cited by
- 887
- References
- 26
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 22 · 2023: 31 · 2022: 31 · 2021: 47 · 2020: 44 · 2019: 52 · 2018: 72 · 2017: 77 · 2016: 80 · 2015: 123 · 2014: 122 · 2013: 141 · 2012: 8
- FWCI
- 81.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- antiplatelet therapy, coronary stenting, platelet function monitoring, VerifyNow P2Y12 assay, clopidogrel, prasugrel, aspirin, stent thrombosis, bleeding events, glycoprotein IIb/IIIa inhibitors, individualized dosing, major adverse cardiovascular events
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Coronary Disease, Coronary Thrombosis, Female, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Pyridines, Thiophenes, Ticlopidine, Stents, Drug Monitoring, Point-of-Care Systems, Retreatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
